药物基因组学检测的协作咨询考量
本文综述药物基因组学(PGx)检测在临床实施中的转化考量,包括检测选择、患者教育与咨询,以及药师和遗传咨询师参与的服务模式。强调多学科协作可克服实施障碍,为患者提供精准医学服务。
要点
- PGx检测实施需多学科协作,药师与遗传咨询师共同参与咨询
- 检测选择、患者教育和咨询是PGx服务的关键转化环节
- 需关注PGx检测的附带风险、儿童检测及家族性影响
核心结论
- 通过包括遗传咨询师和药师在内的多专科合作,可克服PGx检测的实施障碍,为患者提供高质量的精准医学服务。
研究设计与样本
- 本文为综述,描述PGx检测和咨询服务的转化考量,涵盖检测选择、患者教育与咨询以及服务提供模式。
主要发现
- PGx检测的临床应用增加,但提供服务面临诸多挑战。
- PGx是精准医学的重要组成部分,结合遗传学与临床药理学。
- 综述报告了PGx检测选择、患者教育与咨询,以及药师和遗传咨询师参与咨询的服务模式示例。
- 综述回顾了PGx检测的附带风险、儿童检测及检测的家族性影响示例。
临床怎么用
- 采用多学科方法实施PGx检测和信息传递可能对患者和提供者最有益。
- 通过多专科合作,包括遗传咨询师和药师,可克服PGx检测的实施障碍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Increased use of pharmacogenomic (PGx) testing in the clinical setting has revealed a number of challenges to providing this service. PGx is an important component of precision medicine that brings together the fields of genetics and clinical pharmacology. A model that incorporates a multidisciplinary approach to implementation and information delivery may be the most beneficial to patients and providers. In this review, translational considerations in the provision of PGx testing and counseling services are described. Specifically, we report on the selection of PGx tests, the provision of patient education and counseling, and examples of PGx service delivery models that incorporate counseling by pharmacists and genetic counselors. Examples of ancillary risks associated with PGx testing, testing of children, and familial implications of testing are reviewed. Through multispecialty partnerships, including genetic counselors and pharmacists, implementation obstacles to PGx testing can be overcome to provide quality precision medicine to patients.
引用
- Zierhut HA, Campbell CA, Mitchell AG, et al. Collaborative Counseling Considerations for Pharmacogenomic Tests. Pharmacotherapy. 2017. PMID: 28672074. doi:10.1002/phar.1980
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。